Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment.

The prototypic head and neck squamous cell carcinoma (HNSCC) arises from the mucosal lining of the upper aerodigestive tract, demonstrates squamous differentiation microscopically, involves older men with a long history of cigarette smoking and alcohol consumption, and is treated by multimodality therapy. HNSCC has long been regarded as a uniform disease process requiring a methodical and unwavering therapeutic approach. Divergence in epidemiologic trends among HNSCCs arising from different anatomic sites has introduced a view that, morphologic repetition aside, head and neck cancers form a heterogeneous group. This view has been supported at the molecular genetic level. A more complete understanding of the molecular genetics of head and neck cancer is providing new insights into long-held but poorly comprehended concepts such as field cancerization and is introducing various biomarkers with potential application for diagnosing, staging, monitoring, and prognosticating HNSCC.

[1]  H. Kitchener,et al.  Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. , 2006 .

[2]  A. Howlett,et al.  Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. , 1999, Advances in experimental medicine and biology.

[3]  S. Patil,et al.  Human papillomavirus (HPV)-related oropharyngeal nonkeratinizing squamous cell carcinoma: characterization of a distinct phenotype. , 2006, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[4]  J. Manola,et al.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.

[5]  A. Bozec,et al.  Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts , 2007, British Journal of Cancer.

[6]  J. Taube,et al.  Inverse Relationship between Human Papillomavirus-16 Infection and Disruptive p53 Gene Mutations in Squamous Cell Carcinoma of the Head and Neck , 2008, Clinical Cancer Research.

[7]  W. Hong,et al.  Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  David Elashoff,et al.  Salivary Transcriptome Diagnostics for Oral Cancer Detection , 2004, Clinical Cancer Research.

[9]  J. Califano,et al.  Intraoperative molecular margin analysis in head and neck cancer. , 2004, Archives of otolaryngology--head & neck surgery.

[10]  A. Venuti,et al.  Human papillomavirus therapeutic vaccines in head and neck tumors , 2007, Expert review of anticancer therapy.

[11]  Suzanne L Wolden,et al.  Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Macková,et al.  Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara , 2005, Cancer Immunology, Immunotherapy.

[13]  J. Freeman,et al.  Diagnosis of nasopharyngeal carcinoma by DNA amplification of tissue obtained by fine-needle aspiration. , 1992, New England Journal of Medicine.

[14]  J. Baselga,et al.  Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225) , 2004, Clinical Cancer Research.

[15]  A. Garden,et al.  Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[17]  D. Slaughter,et al.  “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin , 1953, Cancer.

[18]  J. Field,et al.  Synchronous oral carcinomas: independent or common clonal origin? , 1998, Cancer research.

[19]  R H Hruban,et al.  Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.

[20]  T. Helliwell,et al.  Second primary tumors in patients with head and neck squamous cell carcinoma , 1995, Cancer.

[21]  J. Califano,et al.  Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  P. Choyke,et al.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan , 2007, Nature Medicine.

[23]  Ekaterina S. Svistun,et al.  Vision enhancement system for detection of oral cavity neoplasia based on autofluorescence , 2004, Head & neck.

[24]  K. Shah,et al.  Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  A. Carvalho,et al.  Feasibility of quantitative PCR‐based saliva rinse screening of HPV for head and neck cancer , 2005, International journal of cancer.

[26]  K. Anastos,et al.  Six‐month natural history of oral versus cervical human papillomavirus infection , 2007, International journal of cancer.

[27]  R. Zarbo,et al.  Common clonal origin of synchronous primary head and neck squamous cell carcinomas: analysis by tumor karyotypes and fluorescence in situ hybridization. , 1995, Human pathology.

[28]  D. Sidransky,et al.  Phenotypic and genotypic disparity in premalignant lesions: of calm water and crocodiles. , 1998, Journal of the National Cancer Institute.

[29]  Tae Woo Kim,et al.  Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  R H Hruban,et al.  Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.

[31]  A. Franchi,et al.  Prediction of recurrence by microsatellite analysis in head and neck cancer , 2000, Genes, chromosomes & cancer.

[32]  David C. Thomas,et al.  Real-Time Gap Ligase Chain Reaction , 2004, Clinical Cancer Research.

[33]  D. Sidransky,et al.  Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. , 1994, American journal of surgery.

[34]  S. Lippman,et al.  Predicting cancer development in oral leukoplakia: ten years of translational research. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  D. Rimm,et al.  Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Vollmer,et al.  Basaloid-squamous carcinoma of the tongue, hypopharynx, and larynx: report of 10 cases. , 1986, Human pathology.

[37]  Benjamin D. L. Li,et al.  Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer , 1997, Oncogene.

[38]  R. Day,et al.  Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .

[39]  J. Epstein,et al.  The efficacy of oral lumenoscopy (ViziLite) in visualizing oral mucosal lesions. , 2006, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

[40]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[41]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[42]  D. Sidransky,et al.  Allelic losses in OraTest-directed biopsies of patients with prior upper aerodigestive tract malignancy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  Q. Wei,et al.  Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck , 2007, Head & neck.

[44]  E. Coto,et al.  Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  P. J. Brooks,et al.  DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis. , 2005, Alcohol.

[46]  W. Westra,et al.  Occult tonsillar carcinoma in the unknown primary , 1998, The Laryngoscope.

[47]  C. R. Leemans,et al.  Molecular Diagnosis of Surgical Margins and Local Recurrence in Head and Neck Cancer Patients , 2004, Clinical Cancer Research.

[48]  W. Westra,et al.  Detection of Human Papillomavirus-16 in Fine-Needle Aspirates to Determine Tumor Origin in Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck , 2007, Clinical Cancer Research.

[49]  Carole Fakhry,et al.  Case-control study of human papillomavirus and oropharyngeal cancer. , 2007, The New England journal of medicine.

[50]  Synchronous and metachronous head and neck carcinomas , 1994, Cancer.

[51]  M. Maule,et al.  Association Between Hypermethylated Tumor and Paired Surgical Margins in Head and Neck Squamous Cell Carcinomas , 2007, Clinical Cancer Research.

[52]  Christopher U. Jones,et al.  Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  A. Carvalho,et al.  Trends in incidence and prognosis for head and neck cancer in the United States: A site‐specific analysis of the SEER database , 2005, International journal of cancer.

[54]  J. Walboomers,et al.  p53 mutations in relation to human papillomavirus type 16 infection in squamous cell carcinomas of the head and neck , 1997, International journal of cancer.

[55]  J. Califano,et al.  11:40 AM: A Genetic Progression Model for Head and Neck Cancer: Implications for Field Cancerization , 1996 .

[56]  Li Zhu,et al.  Δ-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway1 , 2000, The Journal of Immunology.

[57]  K. Shah,et al.  Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. , 2004, The Journal of infectious diseases.

[58]  J. Grandis,et al.  Epidermal growth factor receptor biology in head and neck cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  J. Epstein,et al.  Increased allelic loss in toluidine blue-positive oral premalignant lesions. , 2003, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[60]  N D Le,et al.  Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  J. Califano,et al.  Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. , 1996, Cancer research.

[62]  A. Olshan,et al.  p53 mutations in head and neck cancer: new data and evaluation of mutational spectra. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[63]  S. Lippman,et al.  Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment , 1996, Nature Medicine.

[64]  D. Rimm,et al.  Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis , 2005, Clinical Cancer Research.

[65]  M. Zahurak,et al.  Tissue Distribution of Human Papillomavirus 16 DNA Integration in Patients with Tonsillar Carcinoma , 2005, Clinical Cancer Research.

[66]  F. Bosch,et al.  TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer , 1998, Oncogene.

[67]  W. Westra,et al.  Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. , 2008, Journal of the National Cancer Institute.

[68]  H. Dienes,et al.  Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. , 2003, The American journal of pathology.

[69]  L. Turek,et al.  Human Papillomavirus in Oral Exfoliated Cells and Risk of Head and Neck Cancer , 2004 .

[70]  G. Pond,et al.  Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  E. Munck‐Wikland,et al.  Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer , 2006, International journal of cancer.

[72]  C. la Vecchia,et al.  Combined effect of tobacco and alcohol on laryngeal cancer risk: a case–control study , 2002, Cancer Causes & Control.

[73]  D. Lindquist,et al.  The incidence of tonsillar cancer in Sweden is increasing , 2007, Acta oto-laryngologica.

[74]  Ruth Katz,et al.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.

[75]  D. Sidransky,et al.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.

[76]  W. Dinjens,et al.  A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5–8 , 2003, International journal of cancer.

[77]  M. Spitz,et al.  Descriptive epidemiology and risk factors for head and neck cancer. , 2004, Seminars in oncology.

[78]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.

[79]  J. Califano,et al.  Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. , 1999, Journal of the National Cancer Institute.

[80]  M. Hidalgo,et al.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  K. Ang,et al.  Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  E. Sturgis,et al.  Trends in head and neck cancer incidence in relation to smoking prevalence , 2007, Cancer.

[83]  W. Westra,et al.  Basaloid Squamous Cell Carcinoma of the Head and Neck is a Mixed Variant That Can be Further Resolved by HPV Status , 2008, The American journal of surgical pathology.

[84]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[85]  S. Franceschi,et al.  Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review , 2005, Cancer Epidemiology Biomarkers & Prevention.

[86]  E. Vokes,et al.  Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck , 2005, Clinical Cancer Research.

[87]  H. Morgenstern,et al.  Environmental tobacco smoking, mutagen sensitivity, and head and neck squamous cell carcinoma. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[88]  J. Jen,et al.  Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. , 1998, Journal of the National Cancer Institute.

[89]  A. Schueler,et al.  Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Nhu D Le,et al.  Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome. , 2005, Cancer research.

[91]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[92]  J. Pintos,et al.  Effect of smoking cessation and tobacco type on the risk of cancers of the upper aero-digestive tract in Brazil. , 1999, Epidemiology.

[93]  Perry Me The specialised structure of crypt epithelium in the human palatine tonsil and its functional significance. , 1994 .

[94]  T. Wu,et al.  Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. , 2003, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[95]  Steven S. Chang,et al.  Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma , 2008, Clinical Cancer Research.

[96]  L. Turek,et al.  Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers , 2004, International journal of cancer.

[97]  B. Schmidt,et al.  Tongue and tonsil carcinoma , 2005, Cancer.

[98]  I. Kawabata,et al.  Computerized three-dimensional reconstruction of the crypt system of the palatine tonsil. , 1988, Acta oto-laryngologica. Supplementum.

[99]  E. Gabrielson,et al.  Multiple head and neck tumors: evidence for a common clonal origin. , 1996, Cancer research.

[100]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[101]  J. Jen,et al.  Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. , 2001, Cancer research.

[102]  M. Nagarkatti,et al.  Δ-9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response1 , 2005, The Journal of Immunology.